Clinical experience with apixaban in atrial fibrillation: implications of AVERROES
Raffaele De CaterinaInstitute of Cardiology and Center of Excellence on Aging, G d’Annunzio University, Chieti, G Monasterio Foundation, Pisa, ItalyAbstract: Atrial fibrillation is an extremely common arrhythmia, which substantially increases the risk of stroke and thromboembolism. Pre...
Main Author: | De Caterina R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-07-01
|
Series: | Research Reports in Clinical Cardiology |
Online Access: | http://www.dovepress.com/clinical-experience-with-apixaban-in-atrial-fibrillation-implications--a7889 |
Similar Items
-
Secondary prevention of stroke in atrial fibrillation, use of apixaban: ARISTOTLE, AVERROES studies
by: V.A. Parfenov, et al.
Published: (2014-10-01) -
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
by: Vinai C. Bhagirath, et al.
Published: (2017-07-01) -
Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
by: Andrew Martin, et al.
Published: (2012-01-01) -
Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
by: Andrew Martin, et al.
Published: (2012-07-01) -
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)